Alpha-Ketoglutarate and Abdominal Aortic Aneurysm Progression and Rupture
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- RenJi Hospital
- Trial code
- NCT04723888
- Record updated
- 21 February 2021
- Original description
The objective of this project is to define whether nutritional supplement (oral administration with alpha-ketoglutarate) capable of filling-up the citric acid cycle (anaplerotic therapy) can improve outcomes in patients with an abdominal aortic aneurysm of 39-49 mm in diameter on ultrasound imaging. Alpha-ketoglutarate is commonly used as a nutritional supplement specially by athletes to increase muscle strength. They can be mixed with formula or other foods. Subjects will be followed for up to 5 years.Read full original descriptionShow less
The Intervention Effect Of Alpha-Ketoglutarate On Abdominal Aortic Aneurysm Progression and Rupture: A Prospective, Randomized Parallel Controlled Study Based On Large Cohorts
The objective of this project is to define whether nutritional supplement (oral administration with alpha-ketoglutarate) capable of filling-up the citric acid cycle (anaplerotic therapy) can improve outcomes in patients with an abdominal aortic aneurysm of 39-49 mm in diameter on ultrasound imaging. Alpha-ketoglutarate is commonly used as a nutritional supplement specially by athletes to increase muscle strength. They can be mixed with formula or other foods. Subjects will be followed for up to 5 years.
Inclusion: Presence of an infrarenal AAA with a maximum diameter of 39-49 mm; Han nationality; Between 50 years or more, no gender limit; No mental illness; No history of supplement allergy or supplement allergy; Subjects voluntarily participate in this study, sign an informed consent form, have good compliance, and cooperate with follow-up.
Exclusion: Previous infrarenal aortic surgery; Planned major surgery; Have received any other clinical trial treatment within 1 year; Systemic treatment with corticosteroids or other systemic immunomodulatory therapy; Serious concomitant illness associated with life expectancy of less than 2 years；; Severe infections, including but not limited to infections requiring hospitalization, bacteremia, severe pneumonia, etc; Known or suspected inherited connective tissue disorder; Known significant liver disease; Known human immunodeficiency virus infection at the time of screening；; Any other significant and unstable condition that could limit compliance with the trial protocol; Calculated creatinine clearance of less than 30 ml/min; Known aortic dissection.